Clinical Trial Update: Study of Efficacy and Safety of Grazoprevir (MK-5172) + Elbasvir (MK-8742) With or Without Ribavirin for Participants With Hepatitis C Genotype 1, 4, or 6 Infections Who Have Failed Prior Treatment With Pegylated Interferon + Ribavirin (MK-5172-068) [Phase 3]

View source ↗

Summary

Phase 3 trial assessing efficacy and safety of grazoprevir/elbasvir with or without ribavirin in Hepatitis C Genotypes 1, 4, or 6 after prior Peg-IFN/Ribavirin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir (MK-8742) (elbasvir)
• Grazoprevir (MK-5172) (Grazoprevir)
• Ribavirin (ribavirin)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C Infection | Phase 3 | Status: COMPLETED | Results posted: 2016-03-04